NXTC Company Profile and Key Details

Q: Who are the executives of NXTC?

Dr. Lieping Chen M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory BoardDr. Timothy Mayer Ph.D.Chief Operating OfficerMr. Sourav Kundu Ph.D.Senior Vice President of Devel. & ManufacturingDr. Han Myint FACP, M.D.Chief Medical OfficerMr. Steven P. Cobourn CPA, CPAChief Financial OfficerDr. Solomon Langermann Ph.D.Chief Scientific OfficerMr. Michael S. Richman MSBACo-Founder, Chief Executive Officer, Pres & DirectorMr. Kevin G. ShawGen. CounselMs. Stacy RollingerVice President of HRDr. Sebastien MalovesteSenior Vice President of Bus. Devel.

NASDAQ : NXTC

NextCure

$11.09

-0.73-6.18%

At Close 4:00 PM

66.34

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

NextCure, Inc. (NXTC) stock declined over -6.18%, trading at $11.09 on NASDAQ, down from the previous close of $11.82. The stock opened at $11.98, fluctuating between $11.08 and $11.98 in the recent session.

Stock Snapshot

11.82

Prev. Close

29.72M

Market Cap

11.08

Day Low

-0.47

P/E Ratio

-23.81

EPS (TTM)

-1.93

Cash Flow per Share

11.98

Open

2.68M

Number of Shares

11.98

Day High

70.21%

Free Float in %

4.1

Book Value

11.04K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 05, 2026	11.98	11.98	11.08	11.09	11.07K
Feb 04, 2026	11.46	11.98	11.01	11.82	66.8K
Feb 03, 2026	10.93	11.94	10.93	11.20	41.27K
Feb 02, 2026	10.70	11.51	10.70	10.93	43.68K
Jan 30, 2026	10.44	11.49	10.44	10.85	29.12K
Jan 29, 2026	10.51	11.20	10.42	10.42	13.02K
Jan 28, 2026	11.79	12.48	10.50	10.70	29.03K
Jan 27, 2026	12.19	12.20	11.11	11.12	25.41K
Jan 26, 2026	11.60	12.55	11.60	12.20	37.39K
Jan 23, 2026	12.55	12.55	11.04	11.92	23.38K
Jan 22, 2026	12.70	12.90	12.01	12.65	28.27K
Jan 21, 2026	13.17	13.60	12.97	12.99	5.52K
Jan 20, 2026	12.58	13.45	11.57	13.27	20.85K
Jan 16, 2026	12.83	13.40	12.06	12.91	29.74K
Jan 15, 2026	13.24	13.80	12.52	12.87	25.04K
Jan 14, 2026	13.29	13.39	11.52	12.96	25.23K
Jan 13, 2026	13.41	13.41	12.87	13.36	5.4K
Jan 12, 2026	13.27	14.10	13.00	13.38	14.34K
Jan 09, 2026	13.57	13.98	12.91	13.37	50.96K
Jan 08, 2026	13.75	13.75	13.30	13.59	7.49K

Contact Details

Beltsville, MD 20705

United States

https://www.nextcure.com 240 399 4900

About Company

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Stock Peers

ARGX

-30.56-3.59%

argenx SE$820.31 REGN

-8.645-1.12%

Regeneron Pharmaceuticals, Inc.$766.63 UTHR

-3.66-0.76%

United Therapeutics Corporation$478.93 MDGL

-15.19-3.17%

Madrigal Pharmaceuticals, Inc.$463.42 VRTX

-11.71-2.49%

Vertex Pharmaceuticals Incorporated$458.81 ALNY

-20.72-5.89%

Alnylam Pharmaceuticals, Inc.$331.24 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

2.28+0.75%

Praxis Precision Medicines, Inc.$305.62 KRYS

-1.49-0.55%

Krystal Biotech, Inc.$267.64 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

NextCure, Inc. (NASDAQ:NXTC) closed at $11.09 USD, losing -$0.73 (-6.18%) from the previous close of $11.82. The stock is currently mid-range between its 52-week high and low $2.69 and $15.74. With a market capitalization of about $29.72 million, NextCure, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.55). Key stats such as the average daily volume over the past year has been around 42.68 thousand shares, volume is running light vs its 52-week average. Headquartered in Beltsville, MD, NextCure, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael S. Richman, the company employs approximately 43 people and listed since May 09, 2019. NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -8.95%, SMA50 -10.47%, SMA200 41.32%). The stock’s 14-day RSI is 42.53 (neutral), while the ATR of 1.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -29.54% below its high and over 312.57% above its low. Average 10-day trading volume of 32.98 thousand shares is below the 3-month average of 41.18 thousand, indicating normal recent market interest.

Valuation Metrics

NextCure, Inc. trades at a P/E ratio of -0.53, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.29 suggesting the stock is closer to book value. The P/FCF stands at -0.62, also below market averages.

Dividend & Fair Value

NextCure, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.35. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

NextCure, Inc. generated EPS of -$24.19 over the past year. Five-year average earnings growth is 1.53%. Wall Street analysts project EPS growth of 47.43% annually over the next five years. The latest quarter delivered EPS of -$3.22. The next quarter is forecast at -$2.29. Next year's EPS is expected at -$11.65. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $3.00. The high target offers 62.31% upside. The low target suggests -72.95% downside. The mean target is $8.40. This offers -24.26% upside. NextCure, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -20.69%. The prior quarter beat by 144.37%. Over the last six quarters, Apple has recorded several small beats. These include 52.78% in August 01, 2024.

Shareholding & Insider Activity

NextCure, Inc. has 2.68 million shares outstanding. The public float is 1.88 million shares, elevated short interest at 2.11% of float. This equals 55.46 thousand shares. The short ratio is 0.2 days. Institutional investors hold 38.23% of the float. Insiders own 14.79%. Khuong Chau Quang holds 2.71 million shares, ORBIMED ADVISORS LLC has 2.71 million shares and Sofinnova Venture Partners IX, L.P. has 2.67 million shares.

Financial & Profitability Overview

Over the trailing twelve months, NextCure has not generated any revenue. Returns are negative, with ROA at -48.47% and ROE at -54.82%.
On valuation metrics, NextCure trades at a P/E of -0.53, P/S of 0.00 and P/B of 1.29. The current ratio is 2.97 and quick ratio is 2.97. Debt-to-equity is 0.19, supported by a cash flow-to-debt ratio of -11.10.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, NextCure posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $3.68M (margin 0.00%). Operating income was - $67.64M (margin 0.0%). Net income was- $62.72M (EPS - $2.25).
The company ended the quarter with $108.30M in cash and short-term investments, a total debt of $6.61M, and net debt of - $6.48M. Total assets were $129.42M, with equity of $114.42M. Financials further reflected weakness, with operating cash flow of - $52.97M, free cash flow of - $53.79M, and capital expenditures of - $820.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that NextCure, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.53%, with price expected at $9.70 by February 19, 2026, within a range of $8.97 to $10.41 3-Month Outlook: Projected rise of 32.01%, reaching $14.64 by May 05, 2026, with a range of $14.13 to $15.14. 1-Year Outlook: Projected gain of 314.34%, with price at $45.95 by February 05, 2027, within a range of $45.21 to $56.66.

Key Takeaways

NextCure, Inc. (NASDAQ:NXTC) shares are flat -6.48% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows NextCure, Inc. trading at a premium to the broader market with a P/E of -0.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $22.21, suggesting 100.27% upside. Our AI forecast model points to short-term weakness (-12.53% over two weeks), a medium-term rise (32.01% over three months), and a longer-term gain (314.34% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current NextCure, Inc. (NXTC) stock price?

NextCure, Inc. (NASDAQ: NXTC) stock price is $11.09 in the last trading session. During the trading session, NXTC stock reached the peak price of $11.98 while $11.08 was the lowest point it dropped to. The percentage change in NXTC stock occurred in the recent session was -6.18% while the dollar amount for the price change in NXTC stock was - $0.73.

NXTC's industry and sector of operation?

The NASDAQ listed NXTC is part of Biotechnology industry that operates in the broader Healthcare sector. NextCure, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NXTC?

Dr. Lieping Chen M.D., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Dr. Timothy Mayer Ph.D.
Chief Operating Officer
Mr. Sourav Kundu Ph.D.
Senior Vice President of Devel. & Manufacturing
Dr. Han Myint FACP, M.D.
Chief Medical Officer
Mr. Steven P. Cobourn CPA, CPA
Chief Financial Officer
Dr. Solomon Langermann Ph.D.
Chief Scientific Officer
Mr. Michael S. Richman MSBA
Co-Founder, Chief Executive Officer, Pres & Director
Mr. Kevin G. Shaw
Gen. Counsel
Ms. Stacy Rollinger
Vice President of HR
Dr. Sebastien Maloveste
Senior Vice President of Bus. Devel.

How NXTC did perform over past 52-week?

NXTC's closing price is 312.57% higher than its 52-week low of $2.69 where as its distance from 52-week high of $15.74 is -29.54%.

How many employees does NXTC have?

Number of NXTC employees currently stands at 43.

Link for NXTC official website?

Official Website of NXTC is: https://www.nextcure.com

How do I contact NXTC?

NXTC could be contacted at phone 240 399 4900 and can also be accessed through its website. NXTC operates from 9000 Virginia Manor Road, Beltsville, MD 20705, United States.

How many shares of NXTC are traded daily?

NXTC stock volume for the day was 11.04K shares. The average number of NXTC shares traded daily for last 3 months was 42.68K.

What is the market cap of NXTC currently?

The market value of NXTC currently stands at $29.72M with its latest stock price at $11.09 and 2.68M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	43
Beta	1.53
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NXTC Company Profile and Key Details

NextCure

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics